Quick Answer
ProPhase Labs, Inc. reported Total Revenue of $6.77 million for fiscal year 2024.
ProPhase Labs, Inc. — Key Financials by Year
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|
| Total Revenue | $6.77M -80.6% |
$34.98M -71.5% |
$122.65M +55.2% |
$79.04M +444.6% |
$14.51M +47.0% |
$9.88M -24.8% |
| Revenue (ASC 606) | $6.77M -80.6% |
$34.98M -71.5% |
$122.65M +55.2% |
$79.04M +444.6% |
$14.51M +47.0% |
$9.88M -24.8% |
| Net Income | -$53.36M -218.0% |
-$16.78M -190.9% |
$18.46M +194.3% |
$6.27M +395.2% |
-$2.12M +32.5% |
-$3.15M -80.8% |
| Diluted EPS | -$2.61 -166.3% |
-$0.98 -196.1% |
$1.02 +155.0% |
$0.40 +322.2% |
-$0.18 | — |
| Total Assets | $63.20M -31.2% |
$91.93M +4.9% |
$87.65M -1.8% |
$89.30M +184.3% |
$31.41M +155.9% |
$12.27M -40.8% |
| Cash and Equivalents | $678.0K -57.9% |
$1.61M -82.3% |
$9.11M +8.3% |
$8.41M +23.4% |
$6.82M +1470.5% |
$434.0K -72.1% |
| Long-Term Debt | — | $2.92M | $0.00 | — | — | — |
| Stockholders Equity | $7.35M -85.1% |
$49.38M -22.4% |
$63.63M +8.5% |
$58.63M +455.4% |
$10.56M -6.0% |
$11.23M -31.9% |
| R&D Expense | $594.0K -57.6% |
$1.40M +115.0% |
$652.0K +25.4% |
$520.0K -17.9% |
$633.0K +90.7% |
$332.0K -16.6% |
| Operating Income | -$38.63M -82.0% |
-$21.22M -189.9% |
$23.59M +140.7% |
$9.80M +571.0% |
-$2.08M +35.8% |
-$3.24M -98.2% |
| Gross Profit | -$150.0K -101.0% |
$15.56M -78.0% |
$70.65M +68.3% |
$41.99M +811.6% |
$4.61M +76.1% |
$2.62M -45.3% |
| Shares Outstanding | 29.87M +65.6% |
18.05M +11.3% |
16.21M +4.7% |
15.49M +33.5% |
11.60M | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2025 | $883.0K | -37.6% | -29.2% |
| Revenue (ASC 606) | September 30, 2025 | $883.0K | -37.6% | -29.2% |
| Net Income | September 30, 2025 | -$6.84M | -3.8% | -52.9% |
| Diluted EPS | September 30, 2025 | -$0.16 | +54.3% | -45.5% |
| Total Assets | September 30, 2025 | $65.70M | -28.4% | +56.3% |
| Cash and Equivalents | September 30, 2025 | $405.0K | -19.2% | +139.6% |
| Long-Term Debt | March 31, 2016 | $1.47M | — | +0.4% |
| Stockholders Equity | September 30, 2025 | $6.86M | -82.0% | -40.0% |
| R&D Expense | September 30, 2025 | $6.0K | -95.1% | +50.0% |
| Operating Income | September 30, 2025 | -$4.76M | +26.5% | -22.3% |
| Gross Profit | September 30, 2025 | -$123.0K | -157.2% | -116.8% |
| Shares Outstanding | September 30, 2025 | 41.54M | +117.7% | +0.0% |
- ProPhase Labs, Inc. reported Total Revenue of $6.77 million for fiscal year 2024.
- ProPhase Labs, Inc. showed a decrease of -80.6% in Total Revenue compared to the prior fiscal year.
- ProPhase Labs, Inc. reported Revenue (ASC 606) of $6.77 million for fiscal year 2024.
- ProPhase Labs, Inc. showed a decrease of -80.6% in Revenue (ASC 606) compared to the prior fiscal year.
- ProPhase Labs, Inc. reported Net Income of -$53.36 million for fiscal year 2024.
- ProPhase Labs, Inc. showed a decrease of -218.0% in Net Income compared to the prior fiscal year.
- ProPhase Labs, Inc. reported Diluted EPS of $2.61 per share (loss) for fiscal year 2024.
- ProPhase Labs, Inc. showed a decrease of -166.3% in Diluted EPS compared to the prior fiscal year.
- ProPhase Labs, Inc. reported Total Assets of $63.20 million for fiscal year 2024.
- ProPhase Labs, Inc. showed a decrease of -31.2% in Total Assets compared to the prior fiscal year.
- ProPhase Labs, Inc. reported Cash and Equivalents of $678.0 thousand for fiscal year 2024.
- ProPhase Labs, Inc. showed a decrease of -57.9% in Cash and Equivalents compared to the prior fiscal year.
- ProPhase Labs, Inc. reported Long-Term Debt of $2.92 million for fiscal year 2023.
- ProPhase Labs, Inc. reported Stockholders Equity of $7.35 million for fiscal year 2024.
- ProPhase Labs, Inc. showed a decrease of -85.1% in Stockholders Equity compared to the prior fiscal year.
- ProPhase Labs, Inc. reported R&D Expense of $594.0 thousand for fiscal year 2024.
- ProPhase Labs, Inc. showed a decrease of -57.6% in R&D Expense compared to the prior fiscal year.
- ProPhase Labs, Inc. reported Operating Income of -$38.63 million for fiscal year 2024.
- ProPhase Labs, Inc. showed a decrease of -82.0% in Operating Income compared to the prior fiscal year.
- ProPhase Labs, Inc. reported Gross Profit of -$150.0 thousand for fiscal year 2024.
- ProPhase Labs, Inc. showed a decrease of -101.0% in Gross Profit compared to the prior fiscal year.
- ProPhase Labs, Inc. reported Shares Outstanding of 29.87 million shares for fiscal year 2024.
- ProPhase Labs, Inc. showed an increase of +65.6% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: